Clinical Guest Contributors

  1. Delays At The Handoff: Where Breakdowns Occur Among The Sponsor, CRO, And Site 7/23/2026

    Consultant Jason C. Bork identifies 10 of the most common points at which a trial can break down before and after patient recruitment.

  2. The U.S. Clinical Trial Recruiting Pipeline Report – June 2026 7/22/2026

    This WhichTrial report breaks down which drug trials are growing the most and the least, drugs that are no longer being studied, and new drugs to the clinic from May 1 to June 30, 2026.

  3. Pharma R&D Pipeline Productivity: Three Ways To Enhance Bandwidth And Efficiency 7/22/2026

    PA Consulting's Naveed Panjwani explores how to improve pipeline productivity via resource utilization, tech-enabled operations, and execution discipline.

  4. The Cost And ROI Of Agentic AI In Clinical Trials: What Sponsors And CROs Need To Know 7/21/2026

    Beroe Inc. analyst T.G. Prasanna discusses agentic AI for clinical research and how it must be evaluated as a regulated operating cost transformation, with platform, orchestration, compliance, validation, and oversight costs modeled together.

  5. Reduce Friction And Save Time: Revamp Site Training To Focus On Value Over Volume 7/21/2026

    TransCelerate BioPharma members Ashlin Dunne, Anne Marie Inglis, and Ann Katrine Miranda assess the state of site training, examine how training affects trial execution, and discuss a better path forward.

  6. Unlocking Gentler, Cost-Efficient TIL Therapy For Cold Tumors 7/20/2026

    CuraCell Head of Clinical Operations Torbjörn Ström discusses, in the context of CC-38 and CytoPLY-derived tumor-infiltrating lymphocytes (TILs), the utility of named-patient experience, dosing and preconditioning, and T-cell therapy capabilities in cold solid tumors.

  7. What Pistoia Alliance's AI Poll Reveals About Industry Readiness And Regulatory Confidence 7/17/2026

    Pistoia Alliance President Becky Upton, Ph.D., reviews findings from a poll about AI use in clinical research conducted at Clinical Trials Technology Congress (CTTC) that revealed barriers to adoption, early ROI, emerging use cases, and the role of patient-generated data.

  8. Early Patient Education And Community Outreach Are Advancing Representation In Clinical Trials 7/16/2026

    Merck Executive Director, Clinical Trial Patient Representation, Adrelia Allen argues that patient awareness, access, early information, and trust shape are the pillars of patient representation in clinical trials.

  9. The Promise Of Bispecifics In The Quest For Outpatient Immunotherapy 7/15/2026

    START San Antonio's Drew Rasco, MD, reflects on the evolution of immunotherapy and highlights how novel therapies such as bispecifics are both challenging and intriguing for principal investigators (PIs).

  10. Digital Twins Enhance Disease Progression Measurements In FSHD 7/14/2026

    Digital twins can transform trial design by making data more robust and alleviating patient burden. In this interview, Epicrispr CEO Amber Salzman, Ph.D., shares how the company's using it to reliably predict muscle volume change in their trial for a FSHD gene therapy.